Editing European Investment Bank (section)

=== COVID-19 response ===
The European Investment Bank has provided financial resources for both economic impacts of the pandemic and for health-related emergencies, the search for a vaccine against COVID-19, and solutions to slow the spread of the virus.<ref name="eib.org">{{Cite web|title=Coronavirus outbreak: EIB Group's response|url=https://www.eib.org/en/about/initiatives/covid-19-response/index.htm|access-date=2021-04-28|website=EIB.org|language=en}}</ref>

On 26 May 2020, the EIB Board of Directors approved the Pan-European Guarantee Fund (EGF), a €25 billion fund which was endorsed by the European Council as part of the overall [[European Union response to the COVID-19 pandemic|European Union COVID-19 response package]]. All 27 EU Member States were invited to contribute to the fund in the form of guarantees proportional to the respective share in the bank. Using the EGF, the EIB group 'aimed to mobilise' up to €200 billion of additional financing for small and medium-sized European businesses from the private sector.<ref name="theguardian.com">{{Cite web|date=2020-12-02|title=UK approves Pfizer/BioNTech Covid vaccine for rollout next week|url=http://www.theguardian.com/society/2020/dec/02/pfizer-biontech-covid-vaccine-wins-licence-for-use-in-the-uk|access-date=2021-04-28|website=the Guardian|language=en}}</ref> European Union companies are eligible to seek financing from the Pan-European Guarantee Fund if they have financial issues due to the economic implication of the COVID-19 pandemic but could have been able to secure loans under pre-crisis circumstances.<ref name="ReferenceA">{{Cite web|title=EIB Board approves €25 billion Pan-European Guarantee Fund in response to COVID-19 crisis|url=https://www.eib.org/en/press/all/2020-126-eib-board-approves-eur-25-billion-pan-european-guarantee-fund-to-respond-to-covid-19-crisis|access-date=2021-04-28|website=European Investment Bank|language=en}}</ref>

In December 2019, the European Investment Bank signed a €50 million loan to help [[BioNTech]] work on cancer treatments. A new loan worth €100 million was approved in June 2020 to support the company's vaccine trials and manufacturing.<ref>{{Cite web|title=Investment Plan for Europe: European Investment Bank to provide BioNTech with up to €100 million in debt financing for COVID-19 vaccine development and manufacturing|url=https://www.eib.org/en/press/all/2020-144-eib-to-provide-biontech-with-up-to-eur-100-million-in-debt-financing-for-covid-19-vaccine-development-and-manufacturing|access-date=2021-04-28|website=European Investment Bank|language=en}}</ref> BioNTech's COVID-19 vaccine was approved for use by the UK drug regulators in December 2020.<ref name="theguardian.com"/>